

**IgM (Immunoglobulin Mu Heavy Chain) (B-Cell Marker) Antibody - With BSA and Azide
Mouse Monoclonal Antibody [Clone SPM557]
Catalog # AH10506****Specification****IgM (Immunoglobulin Mu Heavy Chain) (B-Cell Marker) Antibody - With BSA and Azide -
Product Information**

Application	WB, IHC-P, IF, FC
Primary Accession	P01871
Other Accession	3507 , 510635 , P20769
Reactivity	Human
Host	Mouse
Clonality	Monoclonal
Isotype	Mouse / IgG1, kappa
Calculated MW	75kDa kDa

**IgM (Immunoglobulin Mu Heavy Chain) (B-Cell Marker) Antibody - With BSA and Azide -
Additional Information****Other Names**

Ig mu chain C region,IGHM

Application Note

WB~~1:1000
IHC-P~~N/A
IF~~1:50~200
FC~~1:10~50

Format

200ug/ml of Ab purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.

Storage

Store at 2 to 8°C.Antibody is stable for 24 months.

Precautions

IgM (Immunoglobulin Mu Heavy Chain) (B-Cell Marker) Antibody - With BSA and Azide is for research use only and not for use in diagnostic or therapeutic procedures.

**IgM (Immunoglobulin Mu Heavy Chain) (B-Cell Marker) Antibody - With BSA and Azide -
Protein Information**

Name IGHM {ECO:0000303|PubMed:11340299, ECO:0000303|Ref.14}

Function

Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into

immunoglobulins- secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:20176268, PubMed:22158414). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:17576170, PubMed:20176268).

Cellular Location


[Isoform 1]: Secreted. Note=During differentiation, B-lymphocytes switch from expression of membrane-bound IgM to secretion of IgM.

IgM (Immunoglobulin Mu Heavy Chain) (B-Cell Marker) Antibody - With BSA and Azide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

IgM (Immunoglobulin Mu Heavy Chain) (B-Cell Marker) Antibody - With BSA and Azide - Images



Formalin-fixed, paraffin-embedded human Tonsil stained with IgM Monoclonal Antibody (SPM557)

IgM (Immunoglobulin Mu Heavy Chain) (B-Cell Marker) Antibody - With BSA and Azide - Background

Recognizes a protein of 75kDa, identified as mu heavy chain of human immunoglobulins. It does not cross-react with alpha (IgA), gamma (IgG), epsilon (IgE), or delta (IgD), heavy chains, T-cells, monocytes, granulocytes, or erythrocytes. This MAb is useful in the identification of leukemias,

plasmacytomas, and certain non-Hodgkin's lymphomas. The most common feature of these malignancies is the restricted expression of a single heavy chain class. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is clonal and therefore malignant.

IgM (Immunoglobulin Mu Heavy Chain) (B-Cell Marker) Antibody - With BSA and Azide - References

Maruyama S, et. al. Activation of human B cells and inhibition of their terminal differentiation by monoclonal anti-mu antibodies. Journal of Immunology 1985; 135(1):192-9. | Rudich SM, et. al. Human B cell activation. Evidence for diverse signals provided by various monoclonal anti-IgM antibodies. Journal of Experimental Medicine, 1985; 162(4):1236-55